NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 67 filers reported holding NURIX THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,627,651 | +78576.6% | 1,224,892 | 0.0% | 0.51% | -9.7% |
| Q2 2023 | $12,237 | +12.5% | 1,224,892 | 0.0% | 0.57% | +6.4% |
| Q1 2023 | $10,877 | -99.9% | 1,224,892 | 0.0% | 0.53% | -24.7% |
| Q4 2022 | $13,449,314 | -15.7% | 1,224,892 | 0.0% | 0.71% | -21.0% |
| Q3 2022 | $15,960,000 | +2.8% | 1,224,892 | 0.0% | 0.90% | -8.6% |
| Q2 2022 | $15,519,000 | -9.6% | 1,224,892 | 0.0% | 0.98% | +11.5% |
| Q1 2022 | $17,161,000 | -51.6% | 1,224,892 | 0.0% | 0.88% | -35.9% |
| Q4 2021 | $35,461,000 | -3.4% | 1,224,892 | 0.0% | 1.38% | +7.4% |
| Q3 2021 | $36,698,000 | +12.9% | 1,224,892 | 0.0% | 1.28% | +11.8% |
| Q2 2021 | $32,496,000 | -14.7% | 1,224,892 | 0.0% | 1.15% | -11.2% |
| Q1 2021 | $38,082,000 | -5.4% | 1,224,892 | 0.0% | 1.29% | -0.2% |
| Q4 2020 | $40,274,000 | -14.8% | 1,224,892 | -9.6% | 1.30% | -20.7% |
| Q3 2020 | $47,282,000 | – | 1,354,392 | – | 1.63% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ponoi II Management, LLC | 327,123 | $4,583,000 | 10.17% |
| TRV GP III, LLC | 1,922,549 | $26,935,000 | 7.31% |
| Ponoi Management, LLC | 327,122 | $4,583,000 | 5.95% |
| Foresite Capital Management IV, LLC | 1,030,798 | $14,441,000 | 4.04% |
| DAFNA Capital Management LLC | 543,344 | $7,612,000 | 1.98% |
| Soleus Capital Management, L.P. | 1,011,638 | $14,173,000 | 1.83% |
| Bain Capital Life Sciences Investors, LLC | 1,284,313 | $17,993,000 | 1.75% |
| Redmile Group, LLC | 3,018,784 | $42,293,000 | 1.32% |
| WestHill Financial Advisors, Inc. | 283,333 | $3,969,000 | 1.14% |
| Boxer Capital, LLC | 1,224,892 | $17,161,000 | 0.88% |